MARLBOROUGH, Mass.,
Feb. 2, 2015 /PRNewswire/ -- RXi
Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company
focused on discovering, developing and commercializing innovative
therapies addressing major unmet medical needs using RNA-targeted
technologies, today announced that the Company's Chief
Development Officer, Dr. Pamela
Pavco, will present at the 17th Annual BIO CEO
& Investor Conference on Monday,
February 9, 2015 at 9:00 a.m.
EST in New York City. Dr. Pavco will provide an update
on the Company's Dermatology and Ophthalmology Franchises.
Logo -
http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
The presentation will be webcast and available on the
"Investors" section of the Company's website,
www.rxipharma.com.
To schedule a meeting with RXi Pharmaceuticals' management team
at this conference, contact Investor Relations at
ir@rxipharma.com.
About the BIO CEO & Investor Conference
Now in its seventeenth year, the BIO CEO & Investor
Conference is the largest independent investor conference focused
on publicly-traded biotech companies. The conference is designed to
foster an informative dialogue between institutional investors and
senior biotechnology executives about emerging and current
investment opportunities. The conference will be held February 9-10, 2015 at the Waldorf Astoria in
New York City.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a
biotechnology company focused on discovering, developing and
commercializing innovative therapies based on its proprietary,
self-delivering RNAi (sd-rxRNA®) platform. Therapeutics that use
RNA interference, or "RNAi," have great promise because of
their ability to down-regulate the expression of specific genes
that may be over-expressed in disease conditions. Building on the
pioneering work of scientific founder and Nobel Laureate Dr.
Craig Mello, a member of the RXi
Scientific Advisory Board, RXi's first RNAi product candidate,
RXI‑109, a self-delivering RNAi compound (sd-rxRNA®), entered into
human clinical trials in June 2012
and is currently being evaluated in Phase 2 clinical trials to
reduce the formation of dermal scars (fibrosis). RXI-109 is
designed to reduce the expression of connective tissue growth
factor (CTGF), a critical regulator of biological pathways involved
in fibrosis, including scar formation in the skin. RXi's
sd‑rxRNA oligonucleotides are designed for therapeutic use and have
drug-like properties, such as high potency, target specificity,
serum stability, reduced immune response activation, and efficient
cellular uptake. These hybrid oligonucleotide molecules combine the
beneficial properties of conventional RNAi and antisense
technologies. This allows sd‑rxRNAs to achieve efficient
cellular uptake and potent, long-lasting intracellular activity.
For more information, please visit www.rxipharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements
about future expectations, planned and future development of RXi
Pharmaceuticals Corporation's products, technologies and
partnerships. Forward-looking statements about expectations and
development plans of RXi's products and partnerships involve
significant risks and uncertainties such as: the risk that we
may not be able to successfully develop our candidates, or that
development of RNAi-based therapeutics may be delayed or not
proceed as planned, or that we may not develop any RNAi-based
products; risks that the development process for our product
candidates may be delayed, risks related to the development and
commercialization of products by our competitors, the risk related
to our ability to control the timing and terms of collaborations
with third parties, the possibility that other companies or
organizations may assert patent rights preventing us from
developing our products, and risks related to the actual usage or
realization of anticipated benefits of the sales of our common
stock pursuant to the purchase agreement with Lincoln Park Capital
Fund, LLC. Actual results may differ from those contemplated by
these forward-looking statements. RXi does not undertake to update
forward-looking statements to reflect a change in its views, events
or circumstances that occur after the date of this release.
Contact
RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646
tmcgrillen@rxipharma.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-to-present-at-the-17th-annual-bio-ceo--investor-conference-300028923.html
SOURCE RXi Pharmaceuticals Corporation